Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImClone rises on news of licensing deals
ImClone’s financial results were affected by a $75 million payment to settle a 2002 consolidated class-action shareholder lawsuit, which had accused the company of making false or misleading
ImClone’s financial results were affected by a $75 million payment to settle a 2002 consolidated class-action shareholder lawsuit, which had accused the company of making false or misleading
This multi-center, multi-national study is designed to assess the effectiveness of Mylinax in patients with relapsing forms of multiple sclerosis. Endpoints will include assessments of clinical relapses, disability
Prior to the most recent expansion of the existing license agreement, Bristol-Myers Squibb had a non-exclusive license to use prior versions of MorphoSys’ HuCAL library and the AutoCAL
PDL believes the move will help boost the potential value of its ulcerative colitis treatment Nuvion and Roche co-developed organ rejection treatment Zenapax, as well as expanding its
E1-INT is a short course combination therapy aimed at stimulating the regeneration of the body’s insulin-producing cells. This type 2 diabetes clinical trial will be conducted in the
The European patent designates 18 countries in Europe and is in addition to similar patents issued to Pozen in the US and Australia. Equivalent patent applications are pending
Both endpoints were met in the first stage of Adventrx’ two-stage design phase II trial using CoFactor to modulate the effect of 5-fluorouracil (5-FU) in patients with metastatic
Following this affirmative Ministry of Health, Labour and Welfare (MHLW) decision, Enbrel (etanercept) will now be co-promoted by both Wyeth and Takeda Pharmaceutical in Japan. “We are pleased
Under the extension, which was permitted under the terms of the existing agreement, established in December 2003, Merck will continue to contribute drug candidates to the collaboration and
YM BioSciences was advised by its European partner, Oncoscience AG, that a phase II trial in children with brain cancer (glioma) utilizing the EGF receptor monoclonal antibody (h-R3)